Prostate Cancer News, Reviews & Views

No posts with label Mendelian randomization. Show all posts

Home

Subscribe to: Posts (Atom)

Follow by email

Enter your email address:

Delivered by ProstateCancerNewsReviews&Views

Search This Blog

Printfriendly

Blog Archive

▼ 2024 (3)
- ▼ April (1)
  - Pluvicto+Xtandi Delays Progression Better than Xta...
- ► March (1)
- ► January (1)

► 2023 (4)
- ► September (1)
- ► May (1)
- ► April (1)
- ► February (1)

► 2022 (9)
- ► December (1)
- ► October (1)
- ► September (1)
- ► July (1)
- ► June (2)
- ► May (1)
- ► April (1)
- ► January (1)

► 2021 (15)
- ► December (1)
- ► October (1)
- ► August (2)
- ► July (1)
- ► June (2)
- ► May (2)
- ► April (1)
- ► March (1)
- ► February (1)
- ► January (3)

► 2020 (15)
- ► December (3)
- ► September (1)
- ► August (1)
- ► July (1)
- ► June (2)
- ► May (1)
- ► April (5)
- ► February (1)

► 2019 (20)
- ► December (3)
- ► October (1)
- ► September (2)
- ► August (3)
- ► June (2)
- ► May (3)
- ► April (3)
- ► February (2)
- ► January (1)

► 2018 (29)
- ► November (1)
- ► October (7)
- ► September (2)
- ► August (1)
- ► July (4)
- ► April (1)
- ► March (5)
- ► February (3)
- ► January (5)

► 2017 (52)
- ► December (16)
- ► November (3)
- ► October (3)
- ► September (3)
- ► August (2)
- ► July (2)
- ► June (2)
- ► May (3)
- ► March (8)
- ► February (2)
- ► January (8)

► 2016 (117)
- ► December (7)
- ► November (3)
- ► October (3)
- ► September (10)
- ► August (94)

About the Author

Allen Edel is a patient advocate for men with prostate cancer, and has been published in the Journal of Urology. He writes a regular column for the New Prostate Cancer Infolink, and works with support groups.

Read Allen Edel's novels:

Thaw's Hammer (print)
Thaw's Hammer (ebook)
Joan of Quebec (print)
Joan of Quebec (ebook)

Forums I participate in:

HealthUnlocked - Advanced Prostate Cancer
HealthUnlocked - pre-Dx and localized prostate cancer
The New Prostate Cancer InfoLink

Labels

3D-CRT (2)
Ac-225 (6)
active surveillance (7)
acute side effects (1)
adjuvant ADT (22)
adjuvant radiation (11)
ADT (3)
ADT duration (2)
age (3)
ageism (3)
AJCC (1)
alpha emitter (3)
alpha/beta (1)
androgen receptor (2)
antiandrogen (1)
apalutamide (1)
AR-V7 (2)
AS (1)
ASCENDE-RT (3)
ASTRO (1)
ASTRO definition (1)
BAT (3)
BBT (5)
beta emitter (1)
biochemical recurrence (9)
biopsy (2)
BiTE (2)
BMD (1)
bombesin (1)
bone (1)
bounces (2)
BPH (1)
brachy boost (15)
bRFS (6)
BT (4)
cabozantanib (1)
calcium (1)
CAPRA-S (1)
CAR-T (2)
carbon ion (1)
cardiovascular risk (1)
CHAARTED (2)
checkpoint blockers (2)
chemo (3)
CHIiP (1)
clinical trial (29)
cold spots (1)
complementary/alternative medicine. supplements (1)
convenience (1)
cost (2)
Covid-19 (2)
CTC (1)
curcumin (1)
cytoreduction (3)
darolutimide (2)
DART 01/05 (1)
database (1)
debulking (4)
Decipher (3)
decision-making (19)
detection (1)
DNA repair defects (3)
docetaxel (4)
doctors (3)
dose escalation (14)
dose/response curve (1)
DRE (1)
early salvage (12)
early use (1)
EBRT (13)
EBRT +BT (1)
ejaculation (1)
endpoints (3)
EORTC 22991 (1)
EPE (3)
EPIC (6)
ePLND (1)
erectile dysfunction (5)
erectile function (3)
Erleada (4)
exercise (2)
expectant management (1)
experience (1)
F18-DCFPyL (1)
F18-PSMA-1007 (1)
FAPI (1)
fatigue (2)
favorable intermediate risk (5)
Feaxapotide Triflutate (1)
fibroblasts (1)
fiducials (1)
Fluciclovine (2)
focal ablation (6)
focal injection (1)
focal salvage (1)
Fox Chase (1)
Ga-68-PSMA (7)
gay (1)
genetic analysis (3)
genomic classifier (1)
GETUG-AFU 16 (1)
grade (1)
grade progression (1)
GRPR (1)
GS 6 (1)
GS 9/10 (2)
guidelines (2)
HDRBT (12)
heat sink effect (1)
hemiablation (1)
HIFU (2)
high PSA (1)
high risk (25)
high-volume centers (1)
hyperthermia (1)
hypofractionated (15)
hypoxia (1)
I-131-MIP-1095 (3)
iADT (3)
IBD (1)
IIEF (1)
immunotherapy (4)
IMRT (11)
incontinence (3)
index tumor (3)
infection (1)
intermediate risk (9)
invasive procedures (2)
IOBT (1)
ipilimumab (2)
IRE (2)
irrelevance (1)
Jevtana (2)
LATITUDE (2)
LDRBT (12)
LDRBT failure (1)
ligands (1)
LN detection (2)
LN radiation (2)
local recurrence (1)
long term results (8)
long-term ADT (1)
longitudinal study (1)
low risk (3)
Lu-177 (12)
M1 (3)
maximum radiation dose (1)
mCRPC (6)
MDT (1)
Mendelian randomization (1)
metastases (1)
metastasis-directed therapy (3)
metastatic (7)
Metformin (1)
mHSPC (5)
mindfulness (2)
MMAS (1)
monotherapy (4)
morcellation (1)
mortality (1)
mpMRI (2)
multifocal (2)
N1 (7)
Nanoknife (2)
natural history (1)
neoadjuvant ADT (1)
neuroendocrine (1)
nmHSPC (1)
nomogram (3)
non-metastatic recurrence (1)
NPV (1)
Nubeqa (1)
nuclear medicine (4)
oligometastatic (10)
oligorecurrent (3)
omega-3 (1)
oncological control (3)
organs at risk (1)
overall survival (4)
pain palliation (1)
palliative care (1)
PARP inhibitor (3)
patient selection (1)
patient-reported outcomes (6)
PEACE1 (1)
peer-review (1)
PET (9)
PET/MRI (1)
photodynamic therapy (1)
physiological age (1)
platin (1)
PLND (2)
PNI (1)
PORTOS (1)
PPV (1)
prednisone (1)
primary RT (7)
prostate bed only salvage radiation (2)
Prostvac (1)
ProtecT (3)
proton (4)
PSA (1)
PSA nadir (1)
PSMA (12)
PSMA-1007 (1)
PSMA-617 (6)
QOL (2)
Questions for doctors (9)
Ra-223 (2)
radiation oncologists (1)
radiation risk (1)
radiation side effects (5)
radiation vs. surgery (1)
radiation-induced cancers (1)
radiobiology (2)
radiopharmaceutical (6)
radioresistance (1)
RCT (12)
recovery time (1)
rectal spacers (2)
rectal toxicity (7)
recurrence (2)
recurrence after prostatectomy (7)
recurrence after RT (3)
recurrence detection (1)
registry (1)
research design (2)
reverse resistance (1)
RGD (1)
rh-PSMA-7 (1)
risk categories (1)
risk stratification (4)
RP (7)
rPFS (1)
RSI-MRI (1)
RT (1)
RT schedule (3)
RTOG 0415 (1)
RTOG 0902 (1)
Salvage after RT (4)
salvage cryoablation (2)
salvage HDRBT (2)
salvage LDRBT (3)
salvage lymph node radiation (2)
salvage radiation (8)
salvage SBRT (4)
salvage WPRT (5)
SBRT (30)
SBRT boost (2)
SBRT for bone metastases (1)
second opinions (1)
second primary cancer (2)
sequencing (3)
sex effect (1)
sex frequency (1)
sexual function (3)
SF-12 (1)
shared decision-making (1)
SHIM (1)
short-term ADT (3)
SIB (1)
side effects (2)
single fraction (2)
slow growing (1)
small cell (1)
somatostatin (1)
SpaceOAR hydrogel (2)
specialty bias (1)
SRT (14)
stage (1)
Stage T3 (2)
staging (1)
STAMPEDE (3)
standard of care (1)
sublethal killing (1)
supplements (3)
surgery (1)
surrogate endpoint (11)
surrogate endpoints (1)
survival (2)
synergism (1)
T3a (2)
testosterone (2)
Th-227-PSMA (2)
therapy comparison (26)
time to progression (1)
timing of therapy (1)
toxicity (13)
treatment delay (2)
treatment regret (2)
triplet (2)
TRT (5)
TULSA-PRO (1)
TURP (1)
unfavorable intermediate risk (7)
unintended spread (2)
uPSA (3)
urinary toxicity (4)
urologists (1)
utilization (4)
very high risk (3)
vessel sparing (1)
Vitamin D (1)
whole gland ablation (3)
whole gland salvage (2)
whole pelvic radiation (5)
WPRT (4)
xerostomia (1)
Xofigo (3)
Xtandi (5)
Yervoy (1)
Zytiga (5)

Simple theme. Powered by Blogger.